Global Gynecological Cancers Market 2022-2028

Description

List of Tables

Global Gynecological cancers Market Size, Share & Trends Analysis Report By Type (Cervical Cancer, Ovarian Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, and Others (Fallopian Tube Cancer)) By Diagnosis (Colposcopy, Biopsy test Human papillomavirus (HPV) tests, Imaging test) By Therapeutic Modality (Chemotherapy, Radiation Therapy, Hormonal Therapy, Immunotherapy) By End-User (Hospitals and Surgical Centres, Diagnostic Centres, and Others (Research Institutions) Forecast 2022-2028

The global gynecological cancersmarket is anticipated to grow at a substantial CAGR of 17.3% during the forecast period.Gynecologic cancers begin in different places within a woman's pelvis, which is the area below the stomach and in between the hip bones.Each gynecologic cancer is unique, with different signs and symptoms, different risk factors. The different types of gynecologic cancer are cervical cancer, ovarian cancer, uterine cancer, vaginal cancer, and vulvar cancer. Most of the cervical cancer is caused by human papillomavirus (HPV).The growth of the market in the North America is mainly determined by a huge number of R&D activities; financial aids by governments, other private and non-private organizations; collaborations within pharmaceuticals and technology companies and regulatory policies in the country. For instance, according to the American Cancer Society (ACS) in September 2020 updated the guidelines for cervical cancer screening for early detection of cervical cancer. Thus, such active involvement organization is anticipated to support the market growth. Besides this, according to WHO, Cervical Cancer Country Profiles, 2021, the age-standardized cervical cancer incidence rate per 100 000 women in 2020 is estimated to be 6.2.

The global gynecological cancers market is segmented based on type, diagnosis, therapeutic modality and end-users. Based on type the market is segmented into cervical cancer, ovarian cancer, uterine cancer, vaginal cancer, vulvar cancer, and others. Based on diagnosis the market is bifurcated into Colposcopy, Biopsy test Human papillomavirus (HPV) tests, Imaging test . Based on Therapeutic Modality the market is sub-segmented into Chemotherapy, Radiation Therapy, Hormonal Therapy, Immunotherapy. Based on end-user the market is sub-segmented into Hospitals and Surgical Centres, Diagnostic Centres, and Others.Based on the end-user Tthe diagnostic segment is anticipated to grow at the fastest rate, as diagnostic centersis the place where the patients can have proper diagnosis related to cancer and can take medical assistance under observation ofand get experienced healthcare professionalsand high-quality material and equipment. . Also, the increasing number of cancer patients along with growing awareness regarding the various benefits and facilities provided in diagnostics centres is considered a prime factor that isare supporting the growth of the diagnosticsegment.

Geographically market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.North America dominates the market and is expected to continue its presence over the forecast period. The growth can be attributed to the increasing number of ovarian cancer patients andrising obesity in the North America are the main factors supporting the market growth. The obese people are more likely to get cancer compare to healthy person. According to Trust for America's Health, The US adult obesity rate tops 40 %, which is recorded highest.Obesity has serious health consequences including increased risk for type 2 diabetes, high blood pressure, stroke and many types of cancers. Obesity is assessed to increase healthcare spending by $149 billion annually.These factors are significantly increasing the pace of the global gynecological cancer market and diagnosis equipment also.

The major companies serving the global gynecological cancersmarket are Siemens Healthcare GmbH, Pfizer, Inc.andothers. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance,

Research Methodology

The market study of the global gynecological cancersmarket is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market.
Whitepapers, researchpapers, and news blogs.
Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Gynecological cancersMarket Research and Analysis by Type

2. Global Gynecological cancersMarket Research and Analysis by Diagnosis

3. Global Gynecological cancersMarket Research and Analysis by TherapeuticModality

4. Global Gynecological cancersMarket Research and Analysis by End-User

The Report Covers

Comprehensive research methodology of the globalgynecological cancermarket.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global gynecological cancersmarket.
Insights about market determinants that are stimulating the global gynecological cancersmarket.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2019501

Category-Healthcare

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the GlobalGynecological cancersMarket
Recovery Scenario of GlobalGynecological cancersMarket
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. BY Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key CompanyAnalysis
- 3.1.1. Overview
- 3.1.2. Financial Ananlysis
- 3.1.3. SWOT Ananlysis
- 3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players

4. Market Segmentation

4.1. GlobalGynecological CancersMarket, by Type
- 4.1.1. Cervical
- 4.1.2. Ovarian
- 4.1.3. Uterine
- 4.1.4. Vaginal
- 4.1.5. Vulvar
- 4.1.6. Others (Fallopian Tube Cancer)
4.2. Global Gynecological CancersMarket, by Diagnosis
- 4.2.1. Colposcopy
- 4.2.2. Biopsy test
- 4.2.3. Human papillomavirus (HPV) tests
- 4.2.4. Imaging test
- 4.2.5. Others (Pelvic Test)
4.3. Global Gynecological Cancers Market, byTherapeutic Modality
- 4.3.1. Chemotherapy
- 4.3.2. Radiation Therapy
- 4.3.3. Hormonal Therapy
- 4.3.4. Immunotherapy
4.4. Global Gynecological cancers Market, by End-user
- 4.4.1. Hospitals and Surgical Centres
- 4.4.2. Diagnostic Centres
- 4.4.3. Others (Research Institutions)

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Abbott Laboratories, Inc.
6.2. AstraZeneca, PLC
6.3. Becton, Dickinson and Co.
6.4. Boehringer Ingelheim GmbH
6.5. Bristol Myers Squibb Co.
6.6. Caris Life Sciences, Inc.
6.7. Eli Lilly and Co.
6.8. F. Hoffmann-La Roche, Ltd.
6.9. Genentech, Inc.
6.10. GlaxoSmithKline PLC
6.11. Hologic, Inc.
6.12. Janssen Pharmaceuticals, Inc.
6.13. Kazia Therapeutics, Ltd.
6.14. Merck & Co., Inc.
6.15. NuCana PLC
6.16. Pfizer, Inc.
6.17. Sanofi S.A.
6.18. Siemens Healthcare GmbH
6.19. Takeda Pharmaceuticals Co., Ltd.
6.20. Teva Pharmaceuticals, Ltd.